Table 1.

Showing the attenuating effects of PPARγ agonists on plaque level and memory retention in animal model of AD.

S. No.	PPARγ Agonist	Dose (mg/kg b.wt.)	Treatment	Aβ /Plaque Level	Memory Improvement	Refs.
1	Pioglitazone	20	4 months	Decreases	Not assessed	[46]
2	Pioglitazone	40	7 days	Decreases	Not assessed	[45]
3	Rosiglitazone	30	7 months	Decreases	Yes	[46]
4	Pioglitazone	20	6-8 weeks	No change	No	[128]
5	Rosiglitazone	3	12 weeks	Decreases	Yes	[129]
6	Rosiglitazone	5	16 weeks	Decreases	Yes	[128]
7	Rosiglitazone	30	30 days	Not assessed	Yes	[80]
8	Pioglitazone	80	9 days	Decreases	Yes	[36]
9	Pioglitazone	18	14 weeks	Decreases	Yes	[76]
10	Rosiglitazone	30	30 days	No change	Yes	[74]
11	Pioglitazone	15 & 30	21 days	Not assessed	Yes	[80]
12	Rosiglitazone	30	30 days	Not assessed	Yes	[75]